TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7776180

Group type: EXPERIMENTAL
Intervention: Reading combined with coloring pictures
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Activity identified as primary during initial engagement
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Multiple input activities identified as alternatives
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Responses connected to identified activity during initial engagement
Number of subjects: 3
Study: 1971862

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg/day
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 6991164

Group type: EXPERIMENTAL
Intervention: Exogenous androstenedione administration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31050709

Group type: EXPERIMENTAL
Intervention: AKT-inhibitors in combination with first-line chemotherapy
Number of subjects: 0
Study: 28846543

Group type: EXPERIMENTAL
Intervention: Nobori stent (biodegradable polymer-coated biolimus-eluting)
Number of subjects: 2468

Group type: COMPARATOR
Intervention: CYPHER stent (durable polymer-coated sirolimus-eluting)
Number of subjects: 2468
Study: 26457343

Group type: EXPERIMENTAL
Intervention: Fludrocortisone 0.4 mg
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 23292882

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 21302161

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (100 ng/mL plasma)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 19695076

Group type: EXPERIMENTAL
Intervention: Group A (N = 15) - participated in social activity immediately
Number of subjects: 91

Group type: COMPARATOR
Intervention: Group C (N = 60) - did not participate in social activity
Number of subjects: 91
Study: 16904123

Group type: EXPERIMENTAL
Intervention: Exposure to novel words in meaningful text or in isolation; number of exposures manipulated (once, twice, or four times)
Number of subjects: 0
Study: 15087413

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise intervention (45 min, 5 days/week)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Stretching control group
Number of subjects: 173
Study: 11534310

Group type: EXPERIMENTAL
Intervention: Desflurane (group D, n = 31)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Propofol (group P, n = 32)
Number of subjects: 63
Study: 10806672

Group type: EXPERIMENTAL
Intervention: GyneFix IN
Number of subjects: 607

Group type: COMPARATOR
Intervention: TCu 380A
Number of subjects: 607
Study: 7841427

Group type: COMPARATOR
Intervention: Rifampicin
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Rifabutin 150 mg
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Rifabutin 300 mg
Number of subjects: 520
Study: 3394914

Group type: EXPERIMENTAL
Intervention: Oral metoclopramide (10 mg) with oral diazepam (0.2 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Oral diazepam (0.2 mg/kg) alone
Number of subjects: 6
Study: 29677629

Group type: EXPERIMENTAL
Intervention: Supervised moderate intensity physical training (2 sessions per week for 26 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 60
Study: 25790946

Group type: EXPERIMENTAL
Intervention: Rapid palatal expansion (RPE) therapy
Number of subjects: 32
Study: 23940250

Group type: EXPERIMENTAL
Intervention: Installation of heaters in homes
Number of subjects: 309
Study: 21564138

Group type: EXPERIMENTAL
Intervention: Topical cosmetic slimming product combining tetrahydroxypropyl ethylenediamine, caffeine, carnitine, forskolin and retinol
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 18279921

Group type: EXPERIMENTAL
Intervention: Lidocaine spray (5 metered doses of 10% lidocaine)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Lidocaine gel (10 mL)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Plain lubricating gel (10 mL)
Number of subjects: 144
Study: 17702020

Group type: EXPERIMENTAL
Intervention: Face-to-face intervention
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Internet intervention
Number of subjects: 116

Group type: COMPARATOR
Intervention: Delayed treatment control
Number of subjects: 116
Study: 15491234

Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sham treatment (placebo)
Number of subjects: 55
Study: 11165579

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 55
Study: 9644281

Group type: EXPERIMENTAL
Intervention: Symmetrical coordination mode
Number of subjects: 7

Group type: COMPARATOR
Intervention: Asymmetrical coordination mode
Number of subjects: 7
Study: 8195906

Group type: EXPERIMENTAL
Intervention: One-stage screening
Number of subjects: 7856

Group type: COMPARATOR
Intervention: Two-stage screening
Number of subjects: 7856
Study: 3069003

Group type: EXPERIMENTAL
Intervention: Alkalinized 0.5% bupivacaine and 1 in 200,000 adrenaline (group 2)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.5% bupivacaine (group 1)
Number of subjects: 24
Study: 25760652

Group type: EXPERIMENTAL
Intervention: Redesigned labels
Number of subjects: 96

Group type: COMPARATOR
Intervention: Current labels
Number of subjects: 96
Study: 26414004

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week for 12 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 52
Study: 24018240

Group type: EXPERIMENTAL
Intervention: ONO-8539 (30 mg)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: ONO-8539 (100 mg)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: ONO-8539 (300 mg)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Tolterodine (4 mg)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: ONO-8539 (30, 100, 300 mg)
Number of subjects: 435
Study: 22425471

Group type: EXPERIMENTAL
Intervention: Nicotine (6mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 20379684

Group type: EXPERIMENTAL
Intervention: Transbond and halogen light
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Transbond and LED
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fuji Ortho and halogen light
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fuji Ortho and LED
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fuji Ortho, without acid and halogen light
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fuji Ortho, without acid and LED
Number of subjects: 72

Group type: COMPARATOR
Intervention: Halogen light
Number of subjects: 72

Group type: COMPARATOR
Intervention: LED
Number of subjects: 72
Study: 18356686

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg) + Propranolol (80 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Single Aspirin (100 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Single Propranolol (80 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 16238986

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation program
Number of subjects: 180
Study: 12402619

Group type: EXPERIMENTAL
Intervention: rHuEPO (40-70 subcutaneous units/kg weekly)
Number of subjects: 45
Study: 10089839

Group type: EXPERIMENTAL
Intervention: Active rate‐smoothing algorithm
Number of subjects: 240

Group type: COMPARATOR
Intervention: Inactive rate‐smoothing algorithm
Number of subjects: 240
Study: 7538520

Group type: EXPERIMENTAL
Intervention: ipratropium bromide nasal spray 0.03%
Number of subjects: 285
Study: 2213869

Group type: EXPERIMENTAL
Intervention: Stressful life events experienced during each of 6 years of follow-up
Number of subjects: 12866

Group type: COMPARATOR
Intervention: Type A behavior
Number of subjects: 12866
Study: 160741

Group type: EXPERIMENTAL
Intervention: 2 mg cyproterone acetate + 0.05 mg ethinyl estradiol (Diane)
Number of subjects: 0
Study: 31348806

Group type: EXPERIMENTAL
Intervention: OS-Citicoline 500 mg/day for 6 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: No treatment (NN Group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: OS-Citicoline 500 mg/day for 6 months followed by 3 months wash-out (NC Group)
Number of subjects: 36
Study: 28238601

Group type: EXPERIMENTAL
Intervention: ExPEC4V vaccine
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study: 26546896

Group type: EXPERIMENTAL
Intervention: Aquatic exercise for 30 minutes a day, three days a week for six weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group received education and maintained normal life
Number of subjects: 26
Study: 23683140

Group type: EXPERIMENTAL
Intervention: Fast switching to atomoxetine (ATX) over 2 weeks
Number of subjects: 111

Group type: COMPARATOR
Intervention: Slow switching to atomoxetine (ATX) over 10 weeks
Number of subjects: 111
Study: 21311495

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided umbilical catheter placement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional method of umbilical catheter placement
Number of subjects: 0
Study: 18722084

Group type: EXPERIMENTAL
Intervention: Massage as an intervention in the clinical trial sample
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 17535313

Group type: EXPERIMENTAL
Intervention: Asthma education plus contingency management behavioral protocol
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (received instruction on PEF monitoring only)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 77
Study: 15572094

Group type: EXPERIMENTAL
Intervention: More intensive surveillance regimen
Number of subjects: 985

Group type: COMPARATOR
Intervention: Less intensive surveillance regimen
Number of subjects: 985
Study: 11443167

Group type: EXPERIMENTAL
Intervention: Soy protein isolate (40 g soy protein, 118 mg isoflavones)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Casein placebo
Number of subjects: 179
Study: 9532986

Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg four times a day from 36 weeks of gestation until delivery
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg four times a day
Number of subjects: 63
Study: 8032955

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 500 mg/m2 and leucovorin (LV) 500 mg/m2 intravenously weekly for 6 weeks followed by 2 weeks' rest and interferon alfa-2b 8 million units (MU) subcutaneously tiw with no rest period.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and leucovorin (LV) with interferon alfa-2b at doses of 1, 3, 5, 8, or 10 MU.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and leucovorin (LV) with interferon alfa-2b.
Number of subjects: 17
Study: 2558691

Group type: EXPERIMENTAL
Intervention: Fraxiparin (10,000 AXa Institut Choay units)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fraxiparin (various dosages)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fraxiparin
Number of subjects: 8
Study: 270473

Group type: EXPERIMENTAL
Intervention: Continuous treatment with 6-mercaptopurine (6-MP), vincristine, prednisone, and intrathecal methotrexate (MTX)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Additional immunotherapy with BCG or allogenic myeloblasts
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combination of polychemotherapy and immunotherapy with neuraminidase-treated myeloblasts
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ara-C infusion therapy combined with 3 days of daunorubicin and inoculation with methanol extraction supernatant of tubercle bacilli
Number of subjects: 32
Study: 31652237

Group type: EXPERIMENTAL
Intervention: Endurance-type exercise training in the fed state (after consuming breakfast)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Endurance-type exercise training in the fasted state
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Endurance-type exercise training (both groups)
Number of subjects: 25
Study: 30690645

Group type: EXPERIMENTAL
Intervention: Web-based decision aid
Number of subjects: 277

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 277
Study: 27881565

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 or 100 mg daily)
Number of subjects: 2539

Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 2539
Study: 26017715

Group type: EXPERIMENTAL
Intervention: Desmopressin 1.5 microgram
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Desmopressin 5 microgram
Number of subjects: 60

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hypothermia alone
Number of subjects: 60
Study: 23975881

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0
Study: 22166736

Group type: EXPERIMENTAL
Intervention: Fast track surgery protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional care regimen
Number of subjects: 0
Study: 19549403

Group type: EXPERIMENTAL
Intervention: CAG regimen (low-dose cytarabine and aclarubicin with G-CSF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (anthracycline in combination with cytarabine)
Number of subjects: 50
Study: 16839819

Group type: EXPERIMENTAL
Intervention: Education and counselling intervention
Number of subjects: 200
Study: 15189174

Group type: EXPERIMENTAL
Intervention: Chronic renal failure (CRF) patients
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Chronic renal failure (CRF) patients with tHcy ≥ 25 micromol/L
Number of subjects: 315

Group type: COMPARATOR
Intervention: Age- and sex-matched healthy controls
Number of subjects: 315
Study: 11307132

Group type: EXPERIMENTAL
Intervention: Continuous Passive Motion (CPM)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Immobilization
Number of subjects: 43
Study: 9395759

Group type: EXPERIMENTAL
Intervention: Intravenous cyclosporine
Number of subjects: 161

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 161
Study: 7947368

Group type: EXPERIMENTAL
Intervention: celiprolol (200 mg daily)
Number of subjects: 53

Group type: COMPARATOR
Intervention: nifedipine (40 mg daily)
Number of subjects: 53
Study: 3030900

Group type: EXPERIMENTAL
Intervention: ispaghula husk 10 g
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ispaghula husk 20 g
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ispaghula husk 30 g
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ispaghula husk 10 g, 20 g, 30 g (in random order)
Number of subjects: 10
Study: 31811498

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) therapy, administered three times a week during RT.
Number of subjects: 33
Study: 28597973

Group type: EXPERIMENTAL
Intervention: 2 or 4 g/day OM3‐CA
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4 g/day OM3‐CA
Number of subjects: 24
Study: 27738330

Group type: EXPERIMENTAL
Intervention: High serum IL-6 levels
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: High serum CRP levels
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: IL-6 levels in patients with BRAF mutation
Number of subjects: 393
Study: 25630242

Group type: EXPERIMENTAL
Intervention: Mental fatigue
Number of subjects: 8
Study: 23312683

Group type: EXPERIMENTAL
Intervention: Low-flow nasal prongs therapy with room air (1 L/min)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Spontaneous breathing in room air (control)
Number of subjects: 78
Study: 20698734

Group type: EXPERIMENTAL
Intervention: Daily salt intake (18.01 g/day)
Number of subjects: 1970

Group type: EXPERIMENTAL
Intervention: Salt intake in normal weight individuals
Number of subjects: 1970
Study: 18390024

Group type: EXPERIMENTAL
Intervention: Home visits with environmental remediation (n = 153)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Home visits only (n = 128)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Matched control group (n = 115)
Number of subjects: 281
Study: 16869848

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise on a stationary bicycle ergometer
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cognitive distraction task (paced visual serial addition task, PVSAT)
Number of subjects: 40
Study: 14597872

Group type: EXPERIMENTAL
Intervention: Paclitaxel (PAC) 100 mg/m2 infused over 1 hour
Number of subjects: 121

Group type: COMPARATOR
Intervention: Paclitaxel (PAC) 100 mg/m2 infused over 3 hours
Number of subjects: 121
Study: 15136112

Group type: EXPERIMENTAL
Intervention: Highly purified hMG
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recombinant FSH
Number of subjects: 0
Study: 10022422

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chronic renal failure (CRF) children
Number of subjects: 0
Study: 7502550

Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (750 mg per day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (750 mg per day) + Simvastatin (20 mg per day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg per day)
Number of subjects: 18
Study: 2079567

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (10 million units subcutaneously, three times a week for 16 weeks) following 6 weeks of prednisone
Number of subjects: 35

Group type: COMPARATOR
Intervention: Interferon alfa‐2b (10 million units subcutaneously, three times a week for 16 weeks) after 24 weeks of untreated control
Number of subjects: 35
Study: 345884

Group type: EXPERIMENTAL
Intervention: fenoterol
Number of subjects: 30

Group type: COMPARATOR
Intervention: terbutaline
Number of subjects: 30
Study: 30352226

Group type: EXPERIMENTAL
Intervention: Binocular treatment with the dichoptic binocular Dig Rush iPad game (1 hour per day, 5 days per week) for 8 weeks
Number of subjects: 138

Group type: COMPARATOR
Intervention: Continued spectacle correction alone
Number of subjects: 138

Group type: COMPARATOR
Intervention: Comparison of binocular treatment vs. control
Number of subjects: 138
Study: 29225440

Group type: EXPERIMENTAL
Intervention: Nicotine patch use
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Session 8 urges
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Session 1 urges
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Overall decrease in smoking urges
Number of subjects: 308
Study: 25886568

Group type: EXPERIMENTAL
Intervention: eCROPS‐CA intervention for 5 years
Number of subjects: 4320

Group type: COMPARATOR
Intervention: Delayed intervention (control)
Number of subjects: 4320
Study: 24069481

Group type: EXPERIMENTAL
Intervention: Twice-daily application of the plant-based repellent Zanzarin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Availability of closed shoes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 21771745

Group type: EXPERIMENTAL
Intervention: Mixed oral nutritional supplements containing B‐group vitamins
Number of subjects: 236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study: 19448230

Group type: EXPERIMENTAL
Intervention: i.t. morphine (4 microg/kg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: i.t. morphine and clonidine (1 microg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: PCA morphine
Number of subjects: 50
Study: 16894064

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral intervention (Student Bodies) for 8 weeks
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 480
Study: 14662111

Group type: EXPERIMENTAL
Intervention: Flavonoids (specific types not mentioned)
Number of subjects: 0
Study: 11253275

Group type: EXPERIMENTAL
Intervention: 0.05% sodium fluoride + 2.5% xylitol + 2% sorbitol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.05% sodium fluoride + 12.5% xylitol + 2% sorbitol
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.05% sodium fluoride solution
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 50
Study: 9213082

Group type: EXPERIMENTAL
Intervention: 300 mg of sulpiride
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7960687

Group type: EXPERIMENTAL
Intervention: nizatidine 300 mg, once nightly for 4 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: placebo, once nightly for 4 weeks
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: nizatidine 300 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 55
Study: 29083078

Group type: EXPERIMENTAL
Intervention: Cohort of children born in the early 2010s
Number of subjects: 75

Group type: COMPARATOR
Intervention: Cohort of children born in the early 2000s
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Children aged 0-3 years
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Children aged 4-5 years
Number of subjects: 75
Study: 26710892

Group type: EXPERIMENTAL
Intervention: SRP + aPDT
Number of subjects: 30

Group type: COMPARATOR
Intervention: SRP + Doxy
Number of subjects: 30
Study: 24589566

Group type: EXPERIMENTAL
Intervention: Program and active gaming group
Number of subjects: 75

Group type: COMPARATOR
Intervention: Program only group
Number of subjects: 75
Study: 23208457

Group type: EXPERIMENTAL
Intervention: Transtympanic steroid injection plus conventional steroid treatment (TR group, n=27)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conventional steroid treatment (Control group, n=26)
Number of subjects: 53
Study: 20650039

Group type: EXPERIMENTAL
Intervention: Non-concurrent amlodipine dosing (simvastatin at 7:00 PM followed by amlodipine at 11:00 PM)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Concurrent dosing (both drugs at 7:00 PM)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Non-concurrent amlodipine dosing
Number of subjects: 17

Group type: COMPARATOR
Intervention: Concurrent dosing
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both groups (non-concurrent and concurrent)
Number of subjects: 17